<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>MAOIs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i257.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i257.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i257.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i229.htm">Antidepressants</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i255.htm" title="Previous: Trazodone">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i258.htm" title="Next: Isocarboxazid">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i257">MAOIs</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>MAOIs</b>
          has the following interaction information:
        </p><div>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i2.htm" name="_2">ACE Inhibitors</a></td><td> MAOIs possibly enhance hypotensive effect of ACE inhibitors </td><td></td></tr><tr><td><a href="41001i15.htm" name="_15">Adrenergic Neurone Blockers</a></td><td>enhanced hypotensive effect when  MAOIs given with adrenergic neurone blockers </td><td></td></tr><tr><td><a href="41001i20.htm" name="_20">Alcohol</a></td><td class="cBV"><b> MAOIs interact with tyramine found in some beverages containing alcohol and some dealcoholised beverages (hypertensive crisis)—if no tyramine, enhanced hypotensive effect</b></td><td></td></tr><tr><td><a href="41001i26.htm" name="_26">Alpha-blockers</a></td><td>enhanced hypotensive effect when  MAOIs given with alpha-blockers </td><td></td></tr><tr><td><a href="41001i107.htm" name="_107">Angiotensin-II Receptor Antagonists</a></td><td> MAOIs possibly enhance hypotensive effect of angiotensin-II receptor antagonists </td><td></td></tr><tr><td><a href="41001i232.htm" name="_232">Antidepressants, SSRI</a></td><td class="cBV"><b> MAOIs increase CNS effects of SSRIs (risk of serious toxicity)</b></td><td></td></tr><tr><td><a href="41001i241.htm" name="_241">Antidepressants, Tricyclic</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  MAOIs given with tricyclics , tricyclics should not be started until 2 weeks after stopping MAOIs (3 weeks if starting clomipramine or imipramine), also MAOIs should not be started for at least 1–2 weeks after stopping tricyclics (3 weeks in the case of clomipramine or imipramine)</b></td><td></td></tr><tr><td><a href="41001i252.htm" name="_252">Antidepressants, Tricyclic (related)</a></td><td class="cBV"><b>after stopping  MAOIs do not start tricyclic-related antidepressants for 2 weeks, also MAOIs should not be started until at least 1–2 weeks after stopping tricyclic-related antidepressants</b></td><td></td></tr><tr><td><a href="41001i264.htm" name="_264">Antidiabetics</a></td><td> MAOIs possibly enhance hypoglycaemic effect of antidiabetics </td><td></td></tr><tr><td><a href="41001i276.htm">Antiepileptics</a></td><td> MAOIs possibly antagonise anticonvulsant effect of antiepileptics (convulsive threshold lowered)</td><td></td></tr><tr><td><a href="41001i303.htm" name="_303">Antihistamines</a></td><td>increased antimuscarinic and sedative effects when  MAOIs given with antihistamines </td><td>Sedative interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action (including inhalation)</td></tr><tr><td><a href="41001i342.htm" name="_342">Antimuscarinics</a></td><td>increased risk of antimuscarinic side-effects when  MAOIs given with antimuscarinics </td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i24.htm" name="_24">Apraclonidine</a></td><td>avoidance of  MAOIs advised by manufacturer of apraclonidine </td><td></td></tr><tr><td><a href="41001i1009.htm" name="_1009">Atomoxetine</a></td><td class="cBV"><b>after stopping  MAOIs do not start atomoxetine for 2 weeks, also MAOIs should not be started until at least 2 weeks after stopping atomoxetine</b></td><td></td></tr><tr><td><a href="41001i440.htm" name="_440">Beta-blockers</a></td><td>enhanced hypotensive effect when  MAOIs given with beta-blockers </td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i25.htm" name="_25">Brimonidine</a></td><td>avoidance of  MAOIs advised by manufacturer of brimonidine </td><td></td></tr><tr><td><a href="41001i896.htm" name="_896">Bupropion</a></td><td class="cBV"><b>avoidance of bupropion for 2 weeks after stopping  MAOIs advised by manufacturer of bupropion </b></td><td></td></tr><tr><td><a href="41001i427.htm" name="_427">Buspirone</a></td><td>avoidance of  MAOIs advised by manufacturer of buspirone </td><td></td></tr><tr><td><a href="41001i466.htm" name="_466">Calcium-channel Blockers</a></td><td>enhanced hypotensive effect when  MAOIs given with calcium-channel blockers </td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i277.htm" name="_277">Carbamazepine</a></td><td class="cBV"><b>avoidance for 2 weeks after stopping  MAOIs advised by manufacturer of carbamazepine , also antagonism of anticonvulsant effect</b></td><td></td></tr><tr><td><a href="41001i233.htm" name="_233">Citalopram</a></td><td class="cBV"><b>after stopping  MAOIs do not start citalopram for 2 weeks, also MAOIs should not be started until at least 1 week after stopping citalopram</b></td><td></td></tr><tr><td><a href="41001i482.htm" name="_482">Clonidine</a></td><td>enhanced hypotensive effect when  MAOIs given with clonidine </td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>CNS effects of  MAOIs possibly increased by clozapine </b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i522.htm">Diazoxide</a></td><td>enhanced hypotensive effect when  MAOIs given with diazoxide </td><td></td></tr><tr><td><a href="41001i524.htm" name="_524">Diuretics</a></td><td>enhanced hypotensive effect when  MAOIs given with diuretics </td><td></td></tr><tr><td><a href="41001i561.htm" name="_561">Doxapram</a></td><td> MAOIs enhance effects of doxapram </td><td></td></tr><tr><td><a href="41001i1024.htm" name="_1024">Duloxetine</a></td><td class="cBV"><b>after stopping  MAOIs do not start duloxetine for 2 weeks, also MAOIs should not be started until at least 5 days after stopping duloxetine</b></td><td></td></tr><tr><td><a href="41001i854.htm" name="_854">Entacapone</a></td><td class="cBV"><b>avoid concomitant use of non-selective  MAOIs with entacapone </b></td><td></td></tr><tr><td><a href="41001i964.htm" name="_964">Escitalopram</a></td><td class="cBV"><b>after stopping  MAOIs do not start escitalopram for 2 weeks, also MAOIs should not be started until at least 1 week after stopping escitalopram</b></td><td></td></tr><tr><td><a href="41001i234.htm" name="_234">Fluoxetine</a></td><td class="cBV"><b>after stopping  MAOIs do not start fluoxetine for 2 weeks, also MAOIs should not be started until at least 5 weeks after stopping fluoxetine</b></td><td></td></tr><tr><td><a href="41001i235.htm" name="_235">Fluvoxamine</a></td><td class="cBV"><b>after stopping  MAOIs do not start fluvoxamine for 2 weeks, also MAOIs should not be started until at least 1 week after stopping fluvoxamine</b></td><td></td></tr><tr><td><a href="41001i1180.htm" name="_1180">Histamine</a></td><td>avoidance of  MAOIs advised by manufacturer of histamine </td><td></td></tr><tr><td><a href="41001i763.htm" name="_763">Hydralazine</a></td><td>enhanced hypotensive effect when  MAOIs given with hydralazine </td><td></td></tr><tr><td><a href="41001i28.htm" name="_28">Indoramin</a></td><td class="cBV"><b>avoidance of  MAOIs advised by manufacturer of indoramin </b></td><td></td></tr><tr><td><a href="41001i265.htm" name="_265">Insulin</a></td><td> MAOIs enhance hypoglycaemic effect of insulin </td><td></td></tr><tr><td><a href="41001i558.htm" name="_558">Levodopa</a></td><td class="cBV"><b>risk of hypertensive crisis when  MAOIs given with levodopa , avoid levodopa for at least 2 weeks after stopping MAOIs</b></td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  MAOIs given with other MAOIs (avoid for at least 2 weeks after stopping previous MAOIs and then start at a reduced dose)</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i267.htm" name="_267">Metformin</a></td><td> MAOIs enhance hypoglycaemic effect of metformin </td><td></td></tr><tr><td><a href="41001i611.htm" name="_611">Methyldopa</a></td><td class="cBV"><b>avoidance of  MAOIs advised by manufacturer of methyldopa </b></td><td></td></tr><tr><td><a href="41001i718.htm" name="_718">Methylphenidate</a></td><td class="cBV"><b>risk of hypertensive crisis when  MAOIs given with methylphenidate , some manufacturers advise avoid methylphenidate for at least 2 weeks after stopping MAOIs</b></td><td></td></tr><tr><td><a href="41001i764.htm" name="_764">Minoxidil</a></td><td>enhanced hypotensive effect when  MAOIs given with minoxidil </td><td></td></tr><tr><td><a href="41001i823.htm" name="_823">Mirtazapine</a></td><td class="cBV"><b>after stopping  MAOIs do not start mirtazapine for 2 weeks, also MAOIs should not be started until at least 2 weeks after stopping mirtazapine</b></td><td></td></tr><tr><td><a href="41001i262.htm" name="_262">Moclobemide</a></td><td class="cBV"><b>after stopping  MAOIs do not start moclobemide for at least 1 week</b></td><td></td></tr><tr><td><a href="41001i615.htm">Moxonidine</a></td><td>enhanced hypotensive effect when  MAOIs given with moxonidine </td><td></td></tr><tr><td><a href="41001i58.htm" name="_58">Nefopam</a></td><td class="cBV"><b>avoidance of  MAOIs advised by manufacturer of nefopam </b></td><td></td></tr><tr><td><a href="41001i630.htm" name="_630">Nicorandil</a></td><td>enhanced hypotensive effect when  MAOIs given with nicorandil </td><td></td></tr><tr><td><a href="41001i631.htm" name="_631">Nitrates</a></td><td>enhanced hypotensive effect when  MAOIs given with nitrates </td><td></td></tr><tr><td><a href="41001i85.htm">Opioid Analgesics</a></td><td class="cBV"><b>possible CNS excitation or depression (hypertension or hypotension) when  MAOIs given with opioid analgesics—some manufacturers advise avoid concomitant use and for 2 weeks after stopping MAOIs</b></td><td></td></tr><tr><td><a href="41001i236.htm" name="_236">Paroxetine</a></td><td class="cBV"><b>after stopping  MAOIs do not start paroxetine for 2 weeks, also MAOIs should not be started until at least 1 week after stopping paroxetine</b></td><td></td></tr><tr><td><a href="41001i102.htm" name="_102">Pethidine</a></td><td class="cBV"><b>CNS excitation or depression (hypertension or hypotension) when  MAOIs given with pethidine—avoid concomitant use and for 2 weeks after stopping MAOIs</b></td><td></td></tr><tr><td><a href="41001i1185.htm" name="_1185">Pholcodine</a></td><td>avoidance of pholcodine for 2 weeks after stopping  MAOIs advised by manufacturer of pholcodine </td><td></td></tr><tr><td><a href="41001i325.htm" name="_325">Promethazine</a></td><td>avoidance of promethazine for 2 weeks after stopping  MAOIs advised by manufacturer of promethazine </td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td class="cBV"><b>risk of hypertensive crisis when  MAOIs given with rasagiline , avoid MAOIs for at least 2 weeks after stopping rasagiline</b></td><td>Rasagiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i231.htm" name="_231">Reboxetine</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  MAOIs given with reboxetine (MAOIs should not be started until 1 week after stopping reboxetine, avoid reboxetine for 2 weeks after stopping MAOIs)</b></td><td></td></tr><tr><td><a href="41001i862.htm" name="_862">Rizatriptan</a></td><td class="cBV"><b>risk of CNS toxicity when  MAOIs given with rizatriptan (avoid rizatriptan for 2 weeks after MAOIs)</b></td><td></td></tr><tr><td><a href="41001i687.htm" name="_687">Selegiline</a></td><td class="cBV"><b>enhanced hypotensive effect when  MAOIs given with selegiline—manufacturer of selegiline advises avoid concomitant use</b></td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i237.htm" name="_237">Sertraline</a></td><td class="cBV"><b>after stopping  MAOIs do not start sertraline for 2 weeks, also MAOIs should not be started until at least 1 week after stopping sertraline</b></td><td></td></tr><tr><td><a href="41001i765.htm" name="_765">Sodium Nitroprusside</a></td><td>enhanced hypotensive effect when  MAOIs given with sodium nitroprusside </td><td></td></tr><tr><td><a href="41001i268.htm" name="_268">Sulfonylureas</a></td><td> MAOIs enhance hypoglycaemic effect of sulfonylureas </td><td></td></tr><tr><td><a href="41001i574.htm" name="_574">Sumatriptan</a></td><td class="cBV"><b>risk of CNS toxicity when  MAOIs given with sumatriptan (avoid sumatriptan for 2 weeks after MAOIs)</b></td><td></td></tr><tr><td><a href="41001i690.htm" name="_690">Sympathomimetics</a></td><td class="cBV"><b>risk of hypertensive crisis when  MAOIs given with sympathomimetics </b></td><td></td></tr><tr><td><a href="41001i733.htm" name="_733">Tetrabenazine</a></td><td class="cBV"><b>risk of CNS toxicity when  MAOIs given with tetrabenazine (avoid tetrabenazine for 2 weeks after MAOIs)</b></td><td></td></tr><tr><td><a href="41001i1042.htm" name="_1042">Tolcapone</a></td><td>avoid concomitant use of  MAOIs with tolcapone </td><td></td></tr><tr><td><a href="41001i106.htm">Tramadol</a></td><td class="cBV"><b>possible increased serotonergic effects and increased risk of convulsions when  MAOIs given with tramadol—some manufacturers advise avoid concomitant use and for 2 weeks after stopping MAOIs</b></td><td></td></tr><tr><td><a href="41001i263.htm">Tryptophan</a></td><td class="cBV"><b>CNS excitation and confusion when  MAOIs given with tryptophan (reduce dose of tryptophan)</b></td><td></td></tr><tr><td><a href="41001i240.htm">Venlafaxine</a></td><td class="cBV"><b>enhanced CNS effects and toxicity when  MAOIs given with venlafaxine (venlafaxine should not be started until 2 weeks after stopping MAOIs, avoid MAOIs for 1 week after stopping venlafaxine)</b></td><td></td></tr><tr><td><a href="41001i575.htm">Zolmitriptan</a></td><td class="cBV"><b>increased risk of CNS toxicity when  MAOIs given with zolmitriptan </b></td><td></td></tr></tbody></table><p>MAOIs belongs to <b>Antidepressants</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  antidepressants advised by manufacturer of artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td>possible increased risk of convulsions when  antidepressants given with atomoxetine </td><td></td></tr></tbody></table><p><b>Isocarboxazid</b> belongs to
      <b>MAOIs</b>
          but has no specific interaction information.
        </p><p><b>Phenelzine</b> belongs to
      <b>MAOIs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i628.htm">Suxamethonium</a></td><td> phenelzine enhances effects of suxamethonium </td><td></td></tr></tbody></table><p><b>Tranylcypromine</b> belongs to
      <b>MAOIs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i427.htm">Buspirone</a></td><td>manufacturer of  tranylcypromine advises avoid buspirone for 10 days after stopping tranylcypromine</td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i258.htm" title="Isocarboxazid">Isocarboxazid</a></li><li><a href="41001i259.htm" title="Phenelzine">Phenelzine</a></li><li><a href="41001i260.htm" title="Tranylcypromine">Tranylcypromine</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i255.htm">Previous: Trazodone</a> | <a class="top" href="41001i257.htm#">Top</a> | <a accesskey="]" href="41001i258.htm">Next: Isocarboxazid</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>